Xultophy ® 100/3.6 (insulin degludec and liraglutide injection) 100 units/mL and 3.6 mg/mL is a combination of insulin degludec and liraglutide and is indicated as ...
Patient information for Xultophy Including dosage instructions and possible risk factors.
Xultophy is an injection pen containing a combination of insulin degludec and liraglutide. Insulin is a hormone that works by lowering levels of glucose (sugar) in ...
Xultophy 100 units/ml insulin degludec + 3.6 mg/mL liraglutide solution for injection in a pre-filled pen - Summary of Product Characteristics (SPC) by Novo Nordisk ...
European Union agency responsible for the protection of public and animal health through the scientific evaluation and supervision of medicines.
Xultophy EMA/CHMP/424921/2014 Page 2/2 The CHMP, on the basis of quality, safety and efficacy data submitted, considers there to be a favourable benefit-to-risk ...
Xultophy® 100/3.6 is a medicine that combines insulin degludec and liraglutide. Read important safety information, including Boxed Warning, on this page.
Novo Nordisk’s Much-Awaited Basal Insulin/GLP-1 Analogue Combination Xultophy Approved in Europe
Learn about indications, dosage and how it is supplied for the drug Xultophy Injection (Insulin Degludec and Liraglutide).
The R&D pipeline reflects Novo Nordisk’s long-term commitment to driving change to defeat diabetes and other serious chronic conditions.